Top Medical News
3 days ago
Blood pressure (BP) variability is associated with normal-tension glaucomatous optic neuropathy (GON) via the hypoperfusion of the optic nerve, a recent study has found.
5 days ago
Self-reported visual impairment (VI) may increase the odds of dementia among older adults over time, suggests a US study, noting that dementia is similarly predictive of VI over time.
Roshini Claire Anthony, 6 days ago

Patients with youth-onset type 2 diabetes (T2D) are at an increased risk of developing long-term complications, according to follow-up results of the US-based TODAY* study.

6 days ago
Exposure to opioids in the perioperative period appears to result in new persistent use in patients who were previously opioid-naïve, according to a study, which suggests that exposure to opioids is an independent risk factor for persistent use in those undergoing incisional ophthalmic surgery.
09 Sep 2021
Though rare, severe nonproliferative and proliferative diabetic retinopathy remain public health threats, and holistic strategies are needed to control diabetes and other lifestyle risk factors, such as smoking and blood pressure, a new Iran study has found.
Pank Jit Sin, 09 Sep 2021

A new treatment option is now available for the management of wet age-related macular degeneration (AMD). Brolucizumab is the first biologic agent and a new anti-vascular endothelial growth factor (anti-VEGF) designed specifically for intraocular use in humans.

05 Sep 2021
Childhood uveitis not associated with juvenile idiopathic arthritis (JIA) seems to occur very rarely, a recent study has found.
Special Reports
Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 08 Apr 2021
Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.
Roshini Claire Anthony, 28 Jun 2020

Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.

10 Nov 2016
The 2016 Annual Meeting of the American Academy of Ophthalmology (AAO) was held in Chicago, USA, from 15−18 October 2016. A panel of renowned international clinicians in the field of ophthalmology contributed the articles for the Eye on AAO 2016 e-Bulletins, which feature conference highlights, reviews of hot topics discussed at the meeting, Asian and clinical relevance of few of the important topics.